智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300122 智飞生物

交易中 09-24 13:32:24

{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":13.15,"timestamp":1790227944000,"preClose":13.44,"halted":0,"volume":22029751,"delay":0,"changeRate":-0.0216,"floatShares":1414000000,"shares":2394000000,"eps":-6.2385,"marketStatus":"交易中","change":-0.29,"latestTime":"09-24 13:32:24","open":13.33,"high":13.45,"low":13.08,"amount":291000000,"amplitude":0.0275,"askPrice":13.15,"askSize":7,"bidPrice":13.14,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-6.2385,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790233200000},"marketStatusCode":2,"adr":0,"adjPreClose":13.44,"symbolType":"stock","openAndCloseTimeList":[[1790213400000,1790220600000],[1790226000000,1790233200000]],"highLimit":14.78,"lowLimit":12.1,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":2.14,"roa":"--","roe":"--","epsLYR":-6.1506,"committee":0.193115,"marketValue":31478000000,"turnoverRate":0.0156,"status":1,"floatMarketCap":18598000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2669627482","title":"智飞生物：9月23日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2669627482","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669627482?lang=zh_cn&edition=full","pubTime":"2026-09-23 23:01","pubTimestamp":1790175694,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月23日智飞生物发布公告称公司于2026年9月23日召开业绩说明会。相关调整对公司经营业绩的影响，以公司披露的定期报告为准。公司旗下宸安生物研发的利拉鲁肽注射液于今年 7月获批上市，9月正式发货并完成全国首针注射，已投入临床使用。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300041674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2580892789.USD","300122","BK0188","LU2148510915.USD","BK0046","LU1328615791.USD","BK0196","LU2580892862.HKD","LU1064130708.USD","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668185766","title":"智飞生物：截至2026年9月18日，公司普通股股东人数为122,538","url":"https://stock-news.laohu8.com/highlight/detail?id=2668185766","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668185766?lang=zh_cn&edition=full","pubTime":"2026-09-20 17:24","pubTimestamp":1789896245,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问截至2026年9月15日，公司普通股股东人数是多少？谢谢。智飞生物回复：您好，截至2026年9月18日，公司普通股股东人数为122,538，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000007299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1328615791.USD","BK0046","BK0239","LU1064131003.USD","LU2148510915.USD","LU2580892789.USD","300122","BK0188","BK0196","BK0077","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666540384","title":"智飞生物：专一、专注、专业地在生物制药领域深耕","url":"https://stock-news.laohu8.com/highlight/detail?id=2666540384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666540384?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:57","pubTimestamp":1789117034,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，现在投资者很多都已经盼望智飞生物直接退市，本金早已经亏损完了，对公司发展更不抱有任何希望。公司针对这一现实情况，公司的市值管理计划是怎样实施的？效果怎样？请详细回答一下，谢谢。智飞生物回复：您好，公司专一、专注、专业地在生物制药领域深耕，聚焦生产经营稳健发展，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；同时完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100036450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","LU2580892862.HKD","LU1328615791.USD","BK0239","LU1064131003.USD","03069","LU2148510915.USD","BK0046","300122","LU2580892789.USD","LU1064130708.USD","BK0196","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666540877","title":"智飞生物：公司持续践行国际化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2666540877","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666540877?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:57","pubTimestamp":1789117030,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，印度本土药企曼凯制药于8月20日宣布，已与重庆宸安生物制药有限公司达成独家进口授权协议，将在印度市场商业化推广该公司德谷胰岛素以及德谷胰岛素与门冬胰岛素复方制剂，用于治疗1型、2型糖尿病，意在强化曼凯制药在糖尿病，是否属实？公司为何不公布公开？请详细解释一下智飞生物回复：您好，公司持续践行国际化战略，推动自有产品海外市场拓展步伐。公司产品的国际化进展情况请您持续关注公司的信息披露，感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100036447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0046","LU1064131003.USD","LU1064130708.USD","LU2580892862.HKD","BK0188","BK0239","LU1328615791.USD","LU2580892789.USD","300122","BK0077","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326943","title":"智飞生物(300122.SZ)：司美格鲁肽注射液申请生产注册获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326943","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665326943?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:10","pubTimestamp":1788858625,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由公司控股子公司重庆宸安生物制药有限公司研发的司美格鲁肽注射液申请生产注册获得国家药品监督管理局出具的《受理通知书》。该产品Ⅲ期临床研究数据表明，宸安生物研发的司美格鲁肽注射液与原研产品诺和泰临床疗效和安全性相当。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：司美格鲁肽注射液申请生产注册获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1064131003.USD","BK0188","LU1328615791.USD","LU1064130708.USD","LU2580892789.USD","BK0196","LU2580892862.HKD","BK0077","300122","BK0046","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665931105","title":"智飞生物最新公告：重组轮状病毒亚单位疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665931105","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665931105?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:44","pubTimestamp":1788774283,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司全资子公司智飞绿竹研发的重组轮状病毒亚单位疫苗(大肠杆菌)获国家药监局临床试验批准，同意开展预防轮状病毒感染引起的急性胃肠炎的临床试验。该疫苗覆盖全球流行毒株谱系广、安全性高，采用注射途径免疫，具有免疫原性更稳定、持久、接种窗口期更长的特点。若进展顺利，将进一步丰富公司消化道传播疫苗矩阵，完善产品布局。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","LU2580892862.HKD","BK0046","BK0188","300122","BK0077","LU1064130708.USD","LU2148510915.USD","BK0239","159646","BK0196","LU1064131003.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664380706","title":"智飞生物：默沙东将供应九价HPV疫苗等三款协议产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2664380706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664380706?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:51","pubTimestamp":1788511873,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问公司是否还是默沙东的独家代理？是否会代理默沙东的产品？智飞生物回复：您好，公司于2026年4月2日发布《关于与默沙东调整战略合作协议的公告》（2026-20），默沙东将按照协议规定，向公司供应或安排供应九价HPV疫苗（佳达修9）、五价轮状病毒疫苗（乐儿德）、23价肺炎多糖疫苗（纽莫法）三款协议产品。详情请查阅公司在巨潮资讯网披露的公告，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400029392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU2580892789.USD","BK0077","LU1328615791.USD","LU1064131003.USD","300122","BK0046","159646","LU2580892862.HKD","LU1064130708.USD","BK0239","BK0196","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802483","title":"智飞生物：公司有序推进23价肺炎球菌多糖疫苗在海外的上市注册工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802483","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664802483?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:48","pubTimestamp":1788511693,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：公司疫苗产品海外注册、海外市场拓展的最新进展，目前哪些产品已经启动境外申报？智飞生物回复：您好，公司持续践行国际化战略，加快自有产品海外市场拓展步伐。公司有序推进23价肺炎球菌多糖疫苗在海外的上市注册工作；结核诊断产品宜卡（EC）已在泰国等结核病高负担国家启动注册程序。公司国际化进展情况请您持续关注公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400029340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","LU2580892862.HKD","BK0196","LU2148510915.USD","BK0046","LU2580892789.USD","LU1064130708.USD","LU1328615791.USD","300122","BK0188","BK0077","LU1064131003.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664299380","title":"智飞生物：自主在研项目共42项","url":"https://stock-news.laohu8.com/highlight/detail?id=2664299380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664299380?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:48","pubTimestamp":1788511691,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司从疫苗代理到现在的自研疫苗治疗药物双轮驱动，请问具体有哪些新产品？什么时候上市？最近公司有什么利好的事情导致股价突然上涨？智飞生物回复：您好，公司持续开展产品创新，目前自主在研项目共42项，其中处于申报、开展临床试验及申请注册阶段的预防类在研项目29项,已进入不同临床阶段的重点治疗类在研项目 5 项。公司在研管线详情请您关注查阅公司的信息披露，感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400029337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","300122","BK0077","LU1328615791.USD","BK0196","LU2148510915.USD","BK0188","LU1064131003.USD","BK0239","BK0046","LU1064130708.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664245380","title":"智飞生物：公司在售产品有重组带状疱疹疫苗（CHO细胞）","url":"https://stock-news.laohu8.com/highlight/detail?id=2664245380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664245380?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:48","pubTimestamp":1788511691,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：带状疱疹疫苗最近有什么利好消息吗？智飞生物回复：您好，公司在售产品有重组带状疱疹疫苗（CHO细胞），中文商品名：欣安立适。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400029338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1064131003.USD","LU2580892789.USD","BK0239","LU1064130708.USD","LU2580892862.HKD","300122","BK0188","LU2148510915.USD","159646","LU1328615791.USD","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664879773","title":"智飞生物(300122.SZ)：流感病毒裂解疫苗药品补充申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664879773","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664879773?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:07","pubTimestamp":1788509243,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日收到全资子公司安徽智飞龙科马生物制药有限公司报告，由智飞龙科马自主研发的流感病毒裂解疫苗药品补充申请获得国家药品监督管理局出具的《受理通知书》。智飞龙科马的流感病毒裂解疫苗已于2025年9月获批上市，适用于3岁及以上人群预防流感病毒引起的感染性疾病。本次补充申请为流感病毒裂解疫苗在已经获得注册批准的适用人群基础上增加“6-35月龄儿童”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：流感病毒裂解疫苗药品补充申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU2148510915.USD","LU1064130708.USD","LU2580892789.USD","LU1328615791.USD","LU2580892862.HKD","BK0239","300122","BK0046","159646","BK0077","LU1064131003.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664817493","title":"智飞生物（300122）披露回购公司股份进展公告，9月2日股价下跌3.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817493","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664817493?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:15","pubTimestamp":1788358521,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，智飞生物报收于13.64元，较前一交易日下跌3.4%，最新总市值为326.51亿元。该股当日开盘14.29元，最高14.29元，最低13.6元，成交额达6.15亿元，换手率为3.15%。智飞生物于2026年9月2日披露《关于回购公司股份的进展公告》。公告显示，公司于2026年7月20日召开第六届董事会第十二次会议，审议通过《关于回购公司股份方案的议案》，拟使用自有或自筹资金以集中竞价交易方式回购公司A股股份，用于股权激励或员工持股计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200042806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU1064130708.USD","LU2580892789.USD","BK0046","LU1328615791.USD","LU2148510915.USD","300122","BK0077","LU1064131003.USD","BK0239","LU2580892862.HKD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664832774","title":"智飞生物(300122.SZ)：冻干人用狂犬病疫苗(ZFB-3细胞)临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664832774","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664832774?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:05","pubTimestamp":1788253557,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)发布公告，公司于近日获悉，由全资子公司安徽智飞龙科马生物制药有限公司研发的冻干人用狂犬病疫苗(ZFB-3细胞)获得国家药品监督管理局药物临床试验申请受理通知书。该药品用于预防狂犬病。通过接种该疫苗，可剌激机体产生抗狂犬病病毒的免疫力。该药品以公司自主研制的人二倍体细胞株(ZFB-3细胞)作为生产基质，与动物源性细胞狂犬病疫苗相比，理论上局部和全身不良反应发生率更小，且无致瘤性风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","IBBJ","159646","BK0077","BMED","BK0046","LU2580892862.HKD","300122","PSYK","BK0239","MDTX","BK0196","LU1328615791.USD","IBBQ","LU2580892789.USD","LU1064130708.USD","LU1064131003.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663200430","title":"智飞生物中报：现金流持续为正 首款治疗产品获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2663200430","media":"中金财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663200430?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:17","pubTimestamp":1788160623,"startTime":"0","endTime":"0","summary":"近日，智飞生物发布2026年半年报。报告期内，智飞生物坚定贯彻长期发展战略，纵深推进转型升级，强化风险防控体系，经营运行总体企稳。　　尽管短期承压，但从现金流和资产负债表来看，公司经营质量正在持续改善，成为半年报中值得关注的积极信号。　　报告期内，经营活动产生的现金流量净额19.74亿元，同比增长21.64%，已连续六个季度持续为正。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260831/32354605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300122","BK0196","LU2148510915.USD","LU2580892789.USD","LU1064131003.USD","BK4588","BK4585","LU1064130708.USD","LU1328615791.USD","BK0077","BK0188","SPHQ","BK0046","159399","LU2580892862.HKD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663026994","title":"智飞生物半年报：利拉鲁肽商业化落地，预防+治疗双轮驱动重构成长逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2663026994","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663026994?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:05","pubTimestamp":1788141901,"startTime":"0","endTime":"0","summary":"报告期内，在疫苗行业需求波动的大环境之下，公司在夯实经营基本盘同时，研发板块迎来标志性进展：首款治疗类产品利拉鲁肽注射液实现商业化，公司“预防+治疗”协同的战略布局取得阶段性突破，推动企业向创新产品驱动型生物制药企业转型。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788141840511723943","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2580892789.USD","BK0196","BK0046","BK0188","LU1064130708.USD","300122","LU1064131003.USD","LU1328615791.USD","LU2148510915.USD","BK0077","BK0239","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048783","title":"智飞生物（300122）2026年中报简析：净利润同比下降33.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048783?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:27","pubTimestamp":1788042458,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期智飞生物发布2026年中报。根据财报显示，智飞生物净利润同比下降33.35%。截至本报告期末，公司营业总收入40.24亿元，同比下降18.36%，归母净利润-8.09亿元，同比下降33.35%。本文数据来源于智飞生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663165012","title":"智飞生物(300122)8月20日股东户数11.14万户，较上期减少2.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663165012","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663165012?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:16","pubTimestamp":1787995006,"startTime":"0","endTime":"0","summary":"证券之星消息，近日智飞生物披露，截至2026年8月20日公司股东户数为11.14万户，较8月10日减少2498.0户，减幅为2.19%。在生物制品行业个股中，智飞生物股东户数高于行业平均水平，截至8月20日，生物制品行业平均股东户数为3.54万户。根据统计，智飞生物2026年8月10日至2026年8月20日，主力资金净流入2.09亿元，游资资金净流出1.65亿元，散户资金净流出4351.29万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","BK0046","LU2580892789.USD","LU2580892862.HKD","LU1328615791.USD","BK0077","300122","LU1064130708.USD","BK0188","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013923","title":"图解智飞生物中报：第二季度单季净利润同比下降50.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013923","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663013923?lang=zh_cn&edition=full","pubTime":"2026-08-29 03:55","pubTimestamp":1787946946,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物2026年中报显示，上半年度公司主营收入40.24亿元，同比下降18.36%；归母净利润-8.09亿元，同比下降33.35%；扣非净利润-8.06亿元，同比下降29.53%；其中2026年第二季度，公司单季度主营收入18.74亿元，同比下降27.24%；单季度归母净利润-4.2亿元，同比下降50.4%；单季度扣非净利润-4.15亿元，同比下降46.09%；负债率45.05%，投资收益-231.46万元，财务费用1.62亿元，毛利率18.08%。财报数据概要请见下图:本文数据来源于智飞生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900007710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191372482","title":"智飞生物上半年亏损8.085亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191372482","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191372482?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:57","pubTimestamp":1787918260,"startTime":"0","endTime":"0","summary":"8月28日，路透社消息——智飞生物（300122.SZ）公布上半年业绩，净亏损达8.085亿元人民币，折合美元约1.2030亿。这家总部位于重庆的疫苗制造商，其财务表现引发了市场的广泛关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","LU1328615791.USD","LU2148510915.USD","LU1064130708.USD","LU2580892862.HKD","LU1064131003.USD","300122","LU2580892789.USD","BK0077","BK0188","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662693660","title":"智飞生物：该平台已支撑公司带状疱疹mRNA疫苗等多款在研项目有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2662693660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662693660?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:57","pubTimestamp":1787911031,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司mRNA技术目前进展如何？有哪些相关成果？智飞生物回复：您好，目前公司已搭建“七+N”技术平台体系，其中包含mRNA技术平台。该平台已支撑公司带状疱疹mRNA疫苗等多款在研项目有序推进。公司研发项目的情况请您关注公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU2148510915.USD","BK0046","LU1064130708.USD","LU2580892862.HKD","BK0196","BK0077","BK0188","300122","LU2580892789.USD","LU1064131003.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790227947404,"stockEarnings":[{"period":"1week","weight":0.09},{"period":"1month","weight":0.0475},{"period":"3month","weight":0.12},{"period":"6month","weight":-0.1111},{"period":"1year","weight":-0.3648},{"period":"ytd","weight":-0.2878}],"compareEarnings":[{"period":"1week","weight":0.0115},{"period":"1month","weight":0.014},{"period":"3month","weight":-0.0446},{"period":"6month","weight":0.0058},{"period":"1year","weight":0.03},{"period":"ytd","weight":-0.0081}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"122538人(较上一季度减少2.45%)","perCapita":"11541股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":"　　重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、流感病毒裂解疫苗、达舒宸、佳达修9、乐儿德、纽莫法、欣安立适。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}